This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Imagine a hospital where the movement of critical clinical materials is handled by autonomous machines working alongside human couriers. This is not a scene from a science fiction film. It is the current setup at Sheba Medical Center, which the company describes as Israel’s largest hospital and ranked among the world’s top 10. The company behind it is Gix Internet Ltd. (Nasdaq: GIXI), a dual-listed technology firm that has expanded its autonomous logistics project at the hospital into blood and bone marrow deliveries.

Gix Internet announced on October 12, 2026, that its subsidiary, deliverz.ai, has expanded its ongoing project at Sheba Medical Center, which previously covered the delivery of chemotherapy medications. The expansion now includes the delivery of blood and bone marrow specimens. According to the company’s press release, the autonomous robots now transport bone marrow from the hematology department to the laboratory and move donated blood from the donation center to the blood bank. This move represents a step up in responsibility. Delivering chemotherapy medications is already a demanding workflow, and the company describes blood and bone marrow transport as life-critical. The company stated that the system is designed to reduce transport delays, improve traceability, and support earlier availability of diagnostic results.

To understand why this matters, it helps to look at what Gix actually does. Its operating focus is software that acts as the brain. Gix provides an artificial intelligence management and orchestration layer that coordinates autonomous robots, human couriers, and hospital workflows into a single intelligent system. Think of it as the air traffic control system for a busy hospital campus. The robots are the planes, and Gix’s software schedules and assigns deliveries in real time by location, priority and availability from a central operations system. The company describes the platform as robot-agnostic, and at Sheba it coordinates a range of autonomous robots through one unified orchestration platform.

The documents show that this is not a first-time trial. The company noted that thousands of delivery missions have already been completed across indoor and outdoor environments at Sheba. The expansion into blood and bone marrow is a logical next step in a growing scope of use cases. Amir Nardimon, the Chief Executive Officer of Gix, said in the announcement that the company is “moving Physical AI from technology demonstrations into real-world, life-critical operations.” This phrasing is important. It signals that Gix wants hospitals to see the platform as an operating system with a track record of thousands of completed missions at Sheba rather than an experiment.

The strategic thread here is about scale and trust. Gix appears to be using Sheba as a reference site. The company stated that the platform is being introduced to U.S. healthcare organizations. The logic is straightforward. If a system can handle a complex, highly active campus like Sheba Medical Center, the company can point to it when pitching other hospitals. The company’s broader strategy is to extend this same management architecture to additional autonomous systems and complex physical operating environments.

What could this become? If Gix can replicate its Sheba deployment in the United States, hospital logistics could become a meaningful business for deliverz.ai. On the other hand, if the expansion at Sheba encounters any significant operational hiccups, it could slow the momentum for U.S. sales. The company has not provided a timeline for U.S. commercial deployments, so the pace of adoption remains uncertain.

The company presents the expansion as a sign of confidence in its system’s ability to handle critical tasks. The company is not just selling efficiency. It is pitching secure, traceable movement of clinical materials. By reducing transport delays, the system aims to shorten laboratory turnaround times. That is a tangible benefit for clinicians who need results quickly to make treatment decisions. The desk’s reading is that Gix is positioning itself as a critical infrastructure provider rather than just a software vendor, echoing Sheba’s own description of autonomous logistics as critical operational infrastructure. If hospitals come to share that view, the platform would look less like a discretionary IT expense and more like part of the clinical supply chain.

There are risks to consider. The documents do not disclose the financial terms of the Sheba project. We do not know the revenue contribution from this specific site. The company’s broader financial health is not detailed in this announcement. The focus is entirely on operational milestones, which means this release offers no financial figures against which to measure the technology’s potential. The company also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company, which adds another layer of complexity to its corporate structure, though the documents do not detail the financial impact of this stake.

What to watch: The next steps are clear. The company says further expansion at Sheba is planned to include additional medication and diagnostic specimen transport workflows. The platform is being introduced to U.S. healthcare organizations. The signposts are announcements regarding specific U.S. hospital partnerships or pilot programs. The company has not provided a date for these U.S. deployments, so any news in this area will be a key indicator of execution. The rollout of the additional workflows at Sheba will also be a visible measure of progress.

In other words, Gix Internet is using Israel’s largest hospital to show that its AI logistics platform can handle life-critical deliveries, and it is now introducing that platform to U.S. healthcare organizations.

Sources